Literature DB >> 21569815

Cellular vaccination with bone marrow-derived dendritic cells pulsed with a peptide of Leishmania infantum KMP-11 and CpG oligonucleotides induces protection in a murine model of visceral leishmaniasis.

Maria Agallou1, Maritsa Margaroni, Evdokia Karagouni.   

Abstract

The use of dendritic cells (DCs) pulsed with defined Leishmania antigens could be a potential immune intervention tool for the induction of protection against infection. In the present study, bone marrow-derived DCs (BM-DCs) pulsed ex vivo with the peptide 12-31aa portion of kinetoplastid membrane protein (KMP)-11 (KMP-11(12-31aa) peptide) acquired a semimature phenotype expressing IL-12 and IL-10, whereas pulsing with the combination of the peptide and CpG oligodeoxynucleotides (ODNs) resulted in their functional maturation expressing mainly IL-12. Vaccination of genetically susceptible to parasite BALB/c mice with both peptide-pulsed BM-DCs elicited a peptide-specific mixed Th1/Th2 immune response, characterized by the production of IFNγ, IL-10 and IgG1 and IgG2a isotype antibodies. However, only BM-DCs pulsed with the combination of KMP-11(12-31aa) peptide and CpG ODNs induced the differentiation of peptide-specific Th17 cells, indicating the adjuvanticity of CpG ODNs. When BALB/c mice were vaccinated with KMP-11(12-31aa) peptide-pulsed BM-DCs, they exhibited only partial protection against Leishmania infantum challenge, whereas (KMP-11(12-31aa) peptide+CpG ODNs)-pulsed BM-DCs reduced efficiently the parasite load in visceral organs. Protective immunity was correlated with restoration of lymphoproliferative responses and a modulation of parasite-specific cellular responses towards Th1 and Th17 profile, confirmed by the isotype switching towards IgG2a, the enhanced production of IFNγ against IL-10, the absence of TGF-β and the overproduction of IL-17. Thus, ex vivo antigen-pulsed BM-DCs represent a powerful tool for the study of protective immune responses against leishmanial infection. Moreover, these findings suggest the use of BM-DCs as effective tools in antigen and adjuvant screening in the design of a protective vaccine against leishmaniasis and other pathogen-related infections.
Copyright © 2011 Elsevier Ltd. All rights reserved.

Entities:  

Mesh:

Substances:

Year:  2011        PMID: 21569815     DOI: 10.1016/j.vaccine.2011.04.089

Source DB:  PubMed          Journal:  Vaccine        ISSN: 0264-410X            Impact factor:   3.641


  24 in total

Review 1.  Identifying vaccine targets for anti-leishmanial vaccine development.

Authors:  Shyam Sundar; Bhawana Singh
Journal:  Expert Rev Vaccines       Date:  2014-04       Impact factor: 5.217

2.  GK1 Improves the Immune Response Induced by Dendritic Cells of BALB/c Mice Infected with Leishmania mexicana Promastigotes.

Authors:  Laila Gutiérrez-Kobeh; Arturo A Wilkins-Rodríguez
Journal:  Acta Parasitol       Date:  2019-09-30       Impact factor: 1.440

3.  DNA prime-protein boost vaccine encoding HLA-A2, HLA-A24 and HLA-DR1 restricted epitopes of CaNA2 against visceral leishmaniasis.

Authors:  Jinlei He; Fan Huang; Jianhui Zhang; Han Chen; Qiwei Chen; Junrong Zhang; Jiao Li; Zhiwan Zheng; Dali Chen; Jianping Chen
Journal:  Immunology       Date:  2018-10-24       Impact factor: 7.397

4.  UCP2 deficiency helps to restrict the pathogenesis of experimental cutaneous and visceral leishmaniosis in mice.

Authors:  Javier Carrión; M Angeles Abengozar; María Fernández-Reyes; Carlos Sánchez-Martín; Eduardo Rial; Gustavo Domínguez-Bernal; M Mar González-Barroso
Journal:  PLoS Negl Trop Dis       Date:  2013-02-21

5.  Mitigating an undesirable immune response of inherent susceptibility to cutaneous leishmaniosis in a mouse model: the role of the pathoantigenic HISA70 DNA vaccine.

Authors:  Gustavo Domínguez-Bernal; Pilar Horcajo; José A Orden; Ricardo De La Fuente; Aldara Herrero-Gil; Lara Ordóñez-Gutiérrez; Javier Carrión
Journal:  Vet Res       Date:  2012-08-09       Impact factor: 3.683

6.  Vaccine Development Against Leishmania donovani.

Authors:  Amrita Das; Nahid Ali
Journal:  Front Immunol       Date:  2012-05-15       Impact factor: 7.561

7.  HisAK70: progress towards a vaccine against different forms of leishmaniosis.

Authors:  Gustavo Domínguez-Bernal; Pilar Horcajo; José A Orden; José A Ruiz-Santa-Quiteria; Ricardo De La Fuente; Lara Ordóñez-Gutiérrez; Abel Martínez-Rodrigo; Alicia Mas; Javier Carrión
Journal:  Parasit Vectors       Date:  2015-12-09       Impact factor: 3.876

8.  The Leishmania donovani histidine acid ecto-phosphatase LdMAcP: insight into its structure and function.

Authors:  Amalia Papadaki; Anastasia S Politou; Despina Smirlis; Maria P Kotini; Konstadina Kourou; Thomais Papamarcaki; Haralabia Boleti
Journal:  Biochem J       Date:  2015-05-01       Impact factor: 3.857

Review 9.  Dendritic cell-based approaches in the fight against diseases.

Authors:  Rafael Freitas-Silva; Maria Carolina Brelaz-de-Castro; Valéria Rêgo Pereira
Journal:  Front Immunol       Date:  2014-02-26       Impact factor: 7.561

10.  T helper1/t helper2 cells and resistance/susceptibility to leishmania infection: is this paradigm still relevant?

Authors:  James Alexander; Frank Brombacher
Journal:  Front Immunol       Date:  2012-04-17       Impact factor: 7.561

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.